TRIAL DETAIL

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)

Drug:
Trial Name:
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Terminated
Phase:
3
Start Date 04/01/2009
Age of Trial (yrs) 12.7
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CAMN107DBR01
Sponsor:
Novartis
Patient Contact:
Novartis US: 1-800-340-6843
Contact email:
Contact Phone:
Randomized:
Randomized
IV or Oral:
Trial Notes:
Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg

Arm 1 800mg per day Nilotinib experimental
Arm 2: 800mg per day Imatinib active comparator

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Monteria
Colombia
Buenos Aires
Argentina
Belo Horizonte
Brazil
Porto Alegre
Brazil
Barretos
Brazil
Santo Andre
Brazil
Jau
Brazil
Natal
Brazil
Rio de Janeiro
Brazil
Medellin
Colombia
Hwasun-gun
Republic of Korea
Seoul
Republic of Korea
Daeugu
Republic of Korea
Panama
Panama
Bankok
Thailand
Khon Kaen
40002
Thailand
Songkla
90110
Thailand
Caracas
Venezuela
Sao Paulo/SP
Brazil
11560 University Avenue
Edmonton
AB
T6G 1Z2
Canada
Ottawa
ON
K1H 8L6
Canada
Montreal
QC
H1T 2M4
Canada
Montreal
QC
H2L 4M1
Canada
Bahia Blanca
Argentina
Neuquen
Argentina
Rosario
Argentina
Halifax
NS
Canada
Toronto
ON
Canada
Beijing
China
Chendu
China
Ghangzhou
China
Ghangzhou
China
Shanghai
China
Guadalajara
Mexico
Mexico City
Mexico
Kazan
Russia
Moscow
Russia
Yekaterinburg
Russia